Hypofractionated radiotherapy after prosthetic breast reconstruction
Official title: Randomized Controlled Trial of Postmastectomy Hypofractionated Radiotherapy Versus Conventional Fractionated Radiotherapy in Breast Cancer Patients Undergoing Prosthetic Breast Reconstruction
Run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT07084519 · Data updated 2026-11-12
This study tests whether a shorter, higher-dose radiotherapy course (HFRT) works as safely and effectively as the standard longer course (CFRT) for patients who had a mastectomy with implant reconstruction.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | Women only |
| Enrollment | 506 (estimated) |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Province) |
| Status | Recruiting |
| Started | March 27, 2026 |
| Main results expected | March 27, 2029 |
| Study ends | December 31, 2030 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07084519 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18-75 with high-risk invasive breast cancer after mastectomy and immediate implant-based reconstruction, adequate performance status, no distant metastasis, and completion of standard chemotherapy.
✕Probably not a fit
Patients with prior chest wall radiotherapy, certain advanced disease features, bilateral reconstruction needing radiotherapy, or specific implant-related complications may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 3 interventional trial comparing hypofractionated radiotherapy (HFRT) to conventional fractionated radiotherapy (CFRT) in women with high-risk breast cancer who have undergone total mastectomy with immediate prosthetic reconstruction. Participants are randomized to receive HFRT: 43.5 Gy in 15 fractions over three weeks, or CFRT: 50 Gy in 25 fractions over five weeks. The primary endpoint is the reconstruction failure rate, including implant removal and capsular contracture. Eligible patients are adults with good performance status who completed standard chemotherapy and meet specific tumor and surgical criteria, with no distant metastasis or prior chest wall radiotherapy. The study is conducted at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, in Beijing.
Why it matters
Potential benefit: If HFRT is as safe and effective as CFRT, patients may receive the same cancer control with a shorter treatment time and potentially fewer clinic visits.
How similar studies have gone: Prior radiotherapy studies in breast cancer have shown hypofractionation can be effective; this trial applies HFRT specifically to post-mmastectomy reconstruction scenarios, which is less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female, aged 18-75 years * Karnofsky Performance Status ≥60 * Histopathologically confirmed invasive breast adenocarcinoma * Total mastectomy \[with or without nipple-areolar complex preservation\] + axillary dissection/sentinel lymph node biopsy + implant/expander placement R0 resection with negative margins * pT3 or N2-3 disease; or pT1-2N1 * No distant metastasis * Completed standard neoadjuvant/adjuvant chemotherapy cycles * ≤8 weeks post-chemotherapy or ≤12 weeks post-surgery if no chemotherapy * Signed informed consent Exclusion Criteria: * Prior radiotherapy to chest wall or nodal regions * Pregnancy or lactation * T4 stage disease * Autologous breast reconstruction of the irradiated breast * Pre-radiotherapy local/regional/distant metastasis * Grade ≥3 implant-related adverse events irreversible before radiotherapy * Bilateral breast cancer requiring bilateral radiotherapy * Concurrent/secondary malignancy with disease-free interval \<5 years \[except non-melanoma skin cancer, papillary/follicular thyroid cancer, or cervical carcinoma in situ\] * Active collagen vascular disease, e.g., SLE, scleroderma * Uncontrolled comorbidities: acute cardiovascular disease, substance abuse, or psychiatric disorders
Where it's running
-
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Province, China Recruiting
Study contacts
- Study coordinator: Xuran Zhao, MD
- Email: 923791362@qq.com
- Phone: 86-13661135602
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EndoBreast: Feasibility and outcomes of nipple-sparing endoscopic mastectomy with immediate reconstruction
This observational study tests whether endoscopic nipple-sparing mastectomy with immediate reconstruction is feasible and acceptable for women at risk or with breast cancer.
-
Access My Breast Cancer Care App
A breast cancer care app is being tested to see if it helps patients navigate care, feel more satisfied, and reduce in-person visits.
-
Autologous Fat Grafting vs DIEP flap for reconstructed breast after radiation
This study tests whether autologous fat transfer can provide similar satisfaction and safety to the DIEP flap procedure for women needing breast reconstruction after mastectomy and radiation.
-
Prehabilitation with physiotherapy and mechanical stimulation before LD flap breast reconstruction
This study tests whether prehabilitation with physiotherapy and mechanostimulation improves shoulder pain and mobility for women undergoing breast reconstruction with a latissimus dorsi flap.
-
Fat grafting plus latissimus dorsi muscle flap for delayed breast reconstruction
This will try adding fat grafting to a latissimus dorsi muscle flap to rebuild breasts in women who previously had a mastectomy.
-
Implant-based breast reconstruction after bariatric (weight-loss) surgery
This registry-based project will use national data to see how common breast implants are and whether women who've had bariatric weight-loss surgery have different complication rates after implant-based breast augmentation or reconstruction.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.